---
title: "Sokal score"
slug: "sokal-score"
date: "2023-06-07"
enableToc: false
tags:
- building
---

> [!info]
>
> ğŸŒ± ä¾†è‡ª: [[prognosis of chronic myelogenous leukemia (CML)]]

# Sokal score

* categories:
	* low vs. intermediate vs. high
* calculated from % peripheral blasts, plt count, spleen size, age)
(Blood 1984;63:789)

ä¸€å€‹è€äººã€åœ¨åœ¨å–å•¤é…’ã€ç©è¡€å°æ¿ã€ç„¶å¾Œå°±çˆ†äº†

| Parameter                         | Norm        |
|-----------------------------------|-------------|
| Age                               | 0 - 0 years |
| Spleen size                       | 0 - 12.7cm  |
| Platelet count                    | 150k        |
| % myeloblasts in peripheral blood | 0 - 0%      |

---

| Risk Group   | Sokal Score | 2-year Survival | Median Survival |
|--------------|-------------|-----------------|-----------------|
| Low          | <0.8        | 90%             | 5 years         |
| Intermediate | 0.8â€“1.2     | 65-90%          | 2.5-5 years     |
| High         | >1.2        | 65%             | 2.5 years       |

## ç¾åœ‹æ˜¯å¦æ¡ç”¨EUTOSè©•åˆ†ä¾†è©•ä¼°CMLæ‚£è€…é¢¨éšªå’ŒæŒ‡å°æ²»ç™‚ï¼Ÿ

- æ‘˜è¦ï¼šåœ¨ç¾åœ‹ï¼Œé›–ç„¶[[EUTOS]]è©•åˆ†åœ¨æ…¢æ€§ç²’ç·šç™½è¡€ç—…ï¼ˆCMLï¼‰çš„é…ªæ°¨é…¸æ¿€é…¶æŠ‘åˆ¶åŠ‘æ™‚ä»£æ›´å®¹æ˜“è¨ˆç®—ä¸¦æ›´æº–ç¢ºåœ°è­˜åˆ¥é«˜é¢¨éšªæ‚£è€…ï¼Œä½†å°šæœªè¢«ç¾åœ‹åœ‹å®¶ç¶œåˆç™Œç—‡ç¶²çµ¡ï¼ˆNCCNï¼‰æŒ‡å—æ‰€æ¡ç´ã€‚ç›¸åï¼ŒNCCNæŒ‡å—ä½¿ç”¨Sokalè©•åˆ†ä¾†è©•ä¼°CMLæ‚£è€…çš„é¢¨éšªä¸¦æŒ‡å°æ²»ç™‚ã€‚

- åŸæ–‡ï¼šIn the United States, the EUTOS score, despite being easier to calculate and more accurate in identifying high-risk patients in the era of tyrosine kinase inhibitors, has not been adopted by the National Comprehensive Cancer Network (NCCN) guidelines. Instead, the NCCN guidelines utilize the Sokal Score to assess the risk and guide therapy decisions for chronic myeloid leukemia (CML).
